SLC2A1 and neoplasm: Based on that clinical evidence that TNBC cells frequently overexpress the glucose transporter 1 (GLUT1) for glucose import unlike other major tumor-residing immune cell populations42,43, we select an experimental GLUT1 inhibitor BAY-87644,45 for selective glycolysis inhibition of TNBC cells.